European Archives - Page 693 of 1331 - European Medical Journal

Medical affairs evolution and the future for MSLs

Marc, Helena and the team are joined by Luca Dezzani, Vice President, Oncology Medical Affairs, J&J, to talk all things medical affairs. Listen now!

Achieving first-time launch success

The first-time launch landscape is growing. In an increasing number of cases, it’s emerging biopharma and biotech companies launching new drugs rather than established pharma giants leading the way.

Incidentally Detected PET-CT Imaging Findings Of COVID-19 Pneumonia: A Retrospective Study During Local Pandemic Era

The novel COVID-19 pneumonia is a continuing global pandemic that has caused deaths of 5 million people worldwide as of November…

A Cross-Sectional Survey On the Psychological Effects of COVID-19 on Doctors and Non-doctors in Pakistan

Objective: The COVID-19 pandemic is still showing fluctuating trends and rapidly increasing case numbers, naturally creating a significant…

Men's Health Week special

In this Men’s Health Week special, the GOLD team is joined by Peter Baker, Director, Global Action on Men’s Health and Chumi Khurana, Global

Reverse mentoring: a how-to guide

Reverse mentoring challenges the status quo and flips traditional learning dynamics on their axis. This how-to guide deconstructs what must be considered when building a reverse mentoring scheme in pharma.

VIATRIS: MULTIPLE SCLEROSIS WEBINAR

Early diagnosis, biomarkers and special populations in MS Webinar

Are you up to date on early diagnosis, biomarkers and special populations in MS? Watch the On-demand Viatris Webinar now.

Climate Change and Human Health – Radiology and the Climate

In this episode, Jonathan Sackier hosts Dr Bryan Buckley. Together, they explore the impact of radiology departments on the climate.

Conservative Management in a Patient with Boerhaave Syndrome

Boerhaave syndrome (BS) is a full thickness oesophageal tear. Most cases require surgical correction. In rare cases, conservative…

Overcoming decentralised clinical trial obstacles

How can emergency measures be translated into permanent solutions to increase the power and number of these trials?